| Abstrakt: |
The hypomethylating agent decitabine has recently been approved as a treatment option for patients diagnosed with myelodysplastic syndromes (MDS). In phase II and III studies, decitabine demonstrated durable responses in patients with MDS and delayed time to acute myeloid leukemia transformation or death compared with supportive care. Oncology nurses play an essential role in preparing patients and caregivers for what to expect during decitabine therapy, including possible adverse effects and duration of response. After decitabine treatment has been initiated, oncology nurses can help to assess and manage adverse effects as well as to monitor response to treatment. |
